ADAR1 Capital Management LLC Buys 905,817 Shares of Rallybio Corporation $RLYB

Key Points

• ADAR1 Capital Management increased its Rallybio stake by 4,411.1%, buying 905,817 additional shares to own 926,352 shares, or 17.45% of the company. Institutional investors collectively hold 90.34% of Rallybio’s stock.
• Analyst sentiment remains cautious: Weiss Ratings upgraded Rallybio to “hold,” while Wall Street Zen moved it to “buy”; MarketBeat reports a consensus “Hold” rating.
• Rallybio shares opened at $16.89, near their 52-week high of $17.57, while the company reported a quarterly loss of $1.09 per share—better than the expected $1.28 loss—but continues to post significant negative margins.

ADAR1 Capital Management LLC raised its stake in Rallybio Corporation (NASDAQ:RLYB - Free Report) by 4,411.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 926,352 shares of the company's stock after purchasing an additional 905,817 shares during the period. ADAR1 Capital Management LLC owned 17.45% of Rallybio worth $14,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Rallybio by 73.5% during the second quarter. BlackRock Inc. now owns 30,332 shares of the company's stock worth $485,000 after purchasing an additional 12,846 shares in the last quarter. XTX Topco Ltd raised its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Susquehanna International Group LLP boosted its holdings in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after acquiring an additional 113,031 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after acquiring an additional 2,996 shares in the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after acquiring an additional 373,821 shares during the last quarter. 90.34% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RLYB. Weiss Ratings raised shares of Rallybio from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Wall Street Zen raised shares of Rallybio from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold".

Rallybio Stock Up 0.5%

Rallybio stock opened at $16.89 on Wednesday. The stock has a 50-day moving average price of $16.22 and a 200 day moving average price of $12.43. The company has a market capitalization of $89.69 million, a price-to-earnings ratio of -3.89 and a beta of -0.90. Rallybio Corporation has a 52 week low of $3.67 and a 52 week high of $17.57.

Rallybio (NASDAQ:RLYB - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.28) by $0.19. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.

Rallybio Company Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source